Press Releases

Perrigo Company (NYSE: PRGO; TASE) and its partner Allergan plc (NYSE: AGN) today announced the launch of guaifenesin 1200mg extended-release tablets, the OTC store brand equivalent to Mucinex®...

Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), showcased eight new product SKUs at the 2016 Global Pet Expo: SENTRY® Vantaguard™ 2 and SENTRY® Flea & Tick Collar...

Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), showcased eight new product SKUs at the 2016 Global Pet Expo: PetArmor® Advanced 2 and PetArmor® Flea & Tick Collar...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of the previously...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the Barclays Global Healthcare Conference at 10:15 AM EST on Tuesday, March 15, 2016...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the pricing of the previously...

Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that Perrigo Finance Unlimited...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the Cowen Annual Healthcare Conference at 4:00 PM EST on Monday, March 7, 2016 at the...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joe Papa will present at the RBC Capital Markets Global Healthcare Conference at 8:00 AM EST on Wednesday,...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), announced that a number of key public facing corporate functions will be relocated to Ireland as part of the Company's focused international...

Perrigo Company plc (NYSE: PRGO; TASE) today announced results for the fourth quarter and calendar year ended December 31, 2015. Perrigo's Chairman and CEO Joseph C. Papa commented, "The team...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on March 15, 2016 to shareholders of record on...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will announce financial results for its calendar year and fourth quarter 2015 on Thursday, February 18, 2016 at approximately 6:00...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A®...

Perrigo Company plc (NYSE: PRGO; TASE) announced today that, following the recent recall of certain dosing cups by its supplier, it has initiated a voluntary product recall in the US to the retail...

Perrigo Company plc (NYSE: PRGO; TASE) today increased full-year 2016 adjusted earnings per diluted share guidance to be in a range of $9.50 to $10.10, up from the Company's October 22, 2015...

Allergan plc (NYSE: AGN) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced the launch of combination guaifenesin 600mg and pseudoephedrine HCl 60mg extended-release tablets to...

Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph Papa will present at the 34th Annual J.P. Morgan Healthcare Conference at 8:00 AM PST on Monday, January...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire a portfolio of generic dosage forms and strengths of Retin-A® (tretinoin) from Matawan Pharmaceuticals,...

Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire Entocort® (budesonide) capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to the news that holders of a majority of its shares rejected Mylan's hostile tender offer, thereby expressing...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) issued the following response to Mylan's press release. Mylan is resorting to desperate tactics on the eve of its tender offer...

Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration ("FDA") approval for the generic version of...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today issued the following shareholder letter: November 9, 2015 CORPORATE GOVERNANCE, MYLAN STYLE: A QUESTION OF TRUST Dear...

Perrigo Company plc ("Perrigo," "the Company") (NYSE: PRGO; TASE) today responded to misleading statements regarding Marc Coucke, Perrigo Board member as well as Executive Committee member. In...